Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

Renata Block, PA-C, analyzes a study on how vitiligo affects different socioeconomic groups disproportionately.

Gary M. Owens, MD, discusses the economic costs associated with vitiligo and the impact this disease has had on the US health care system in general.

Expert dermatologists review a case of a 61-year-old female patient with GPP with no personal or family history of the condition.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, reviews the many pathways of generalized pustular psoriasis (GPP), focusing on individualizing therapy for patients with GPP and treatment options.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial diagnosis experience. Jennifer Holman goes on to describe how different patient populations struggle to access quality care.

Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.

Experts in dermatological conditions review the case of a 40-year-old female with a long history of plaque psoriasis, highlighting the psychosocial impact of the disease and the importance of multidisciplinary care.

Audrey Dean and her dermatologist, Jennifer Holman, MD, FAAD, discuss the importance of having a network of support when diagnosed with atopic dermatitis.

Chesahna Kindred, MD, MBA, FAAD, and Renata Block, PA-C, review areas of the body that are typically affected, and are more problematic to manage, in patients with vitiligo. Comorbidities that put certain patients at higher risk than others are also discussed.

A panel of experts discuss the diagnosis and pathophysiology of vitiligo.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, define what differentiates generalized pustular psoriasis (GPP) from other forms of psoriasis and discuss tools for diagnosing GPP.

Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Lakshi Aldredge, MSN, ANP-BC, comments on the role of nurse practitioners and physician assistants in plaque psoriasis treatment management. Jennifer Conner, MPAS, PA-C, reviews the long-term considerations with systemic therapy.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial symptoms and how the disease impacted her quality of life (QoL). Jennifer Holman reflects on how her practice and approaches have changed as she learned more about the daily impact of atopic dermatitis.

A dermatologist and her patient discuss the pathophysiology and major comorbidities of atopic dermatitis (AD), highlighting the main differences between adult and adolescent AD.

Experts in dermatology hypothesize about the management of patients with chronic vs acute GPP episodes.